Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Does Medifast (MED) Have A Place In Your Dividend Portfolio?

Miller Value Partners recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Opportunity Equity Fund posted a return of 47.02% for the quarter (net of fees), outperforming its benchmark, the S&P 500 Index which returned 20.54% in the same quarter. You should check out Miller Value Partners’ top 5 stock picks for investors to buy right now, which could be the biggest winners of the stock market crash.

In the said letter, Miller Value Partners highlighted a few stocks and Medifast Inc (NYSE:MED) is one of them. Medifast Inc (NYSE:MED) is a health and wellness company. Year-to-date, Medifast Inc (NYSE:MED) stock gained 50.9% and on July 24th it had a closing price of $162.12. Here is what Miller Value Partners’ said:

“Medifast Inc. (MED) climbed 123.5% over the period after reporting 1Q results. The company reported revenue of $178.5M beating consensus of $166M with Earnings per Share (EPS) of $1.93 ahead of the $1.32 expected. The company had their highest coach count ever of 32,600, but average revenue per coach was still down to $5,333 compared to $5,817 seen 1Q last year, but was up 2% quarter-over-quarter (QoQ) with 4Q revenue per coach of $5,229. They noted that 85% of revenue is reoccurring with 80% of expenses being variable, but the company still pulled full-year guidance due to uncertainty around COVID. The company maintained their dividend at $1.13, 4.7% yield.”

In Q1 2020, the number of bullish hedge fund positions on Medifast Inc (NYSE:MED)  stock decreased by about 16% from the previous quarter (see the chart here), so a number of other hedge fund managers don’t seem to agree with Medifast’s growth potential. Our calculations showed that Medifast Inc (NYSE:MED)  isn’t ranked among the 30 most popular stocks among hedge funds.

The top 10 stocks among hedge funds returned 185% since the end of 2014 and outperformed the S&P 500 Index ETFs by more than 109 percentage points. We know it sounds unbelievable. You have been dismissing our articles about top hedge fund stocks mostly because you were fed biased information by other media outlets about hedge funds’ poor performance. You could have doubled the size of your nest egg by investing in the top hedge fund stocks instead of dumb S&P 500 ETFs. Below you can watch our video about the top 5 hedge fund stocks right now. All of these stocks had positive returns in 2020.

Video: Top 5 Stocks Among Hedge Funds

At Insider Monkey we scour multiple sources to uncover the next great investment idea. Hedge fund sentiment towards Tesla reached its all time high at the end of 2019 and Tesla shares more than tripled this year. We are trying to identify other EV revolution winners, so we are checking out this under-the-radar lithium stock. We go through lists like the 10 most profitable companies in the world to pick the best large-cap stocks to buy. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. If you want to find out the best healthcare stock to buy right now, you can watch our latest hedge fund manager interview here. You can subscribe to our free enewsletter below to receive our stories in your inbox:

Disclosure: None. This article is originally published at Insider Monkey.